Relapsed or Refractory Classical Hodgkin’s Lymphoma — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Hodgkin lymphoma (HL) is a type of cancer affecting white blood cells called B lymphocytes. It is the most common type of lymphoma in young adults. HL is highly treatable, with a cure rate of over 90% for early-stage disease. However, 5–10% of patients will have a disease that is resistant to initial treatment (refractory disease), and 10–30% of patients will relapse after initial treatment. For patients with relapsed or refractory HL, the standard of care is salvage chemotherapy followed by autologous stem cell transplant (ASCT). However, half of patients will still have disease progression after ASCT. Relapse following ASCT is associated with a very poor prognosis, with a median survival of only 26 months.
Thelansis’s “Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Classical Hodgkin’s Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Relapsed or Refractory Classical Hodgkin’s Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Relapsed or Refractory Classical Hodgkin’s Lymphoma, Relapsed or Refractory Classical Hodgkin’s Lymphoma market outlook, Relapsed or Refractory Classical Hodgkin’s Lymphoma competitive landscape, Relapsed or Refractory Classical Hodgkin’s Lymphoma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
